Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
neuroscience
Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease
BMC Neuroscience, Volume 13, No. 1, Article 97, Year 2012
Notification
URL copied to clipboard!
Description
Background: Cell therapy is a potential therapeutic approach for several neurodegenetative disease, including Huntington Disease (HD). To evaluate the putative efficacy of cell therapy in HD, most studies have used excitotoxic animal models with only a few studies having been conducted in genetic animal models. Genetically modified animals should provide a more accurate representation of human HD, as they emulate the genetic basis of its etiology.Results: In this study, we aimed to assess the therapeutic potential of a human striatal neural stem cell line (STROC05) implanted in the R6/2 transgenic mouse model of HD. As DARPP-32 GABAergic output neurons are predominately lost in HD, STROC05 cells were also pre-differentiated using purmorphamine, a hedgehog agonist, to yield a greater number of DARPP-32 cells. A bilateral injection of 4.5x105 cells of either undifferentiated or pre-differentiated DARPP-32 cells, however, did not affect outcome compared to a vehicle control injection. Both survival and neuronal differentiation remained poor with a mean of only 161 and 81 cells surviving in the undifferentiated and differentiated conditions respectively. Only a few cells expressed the neuronal marker Fox3.Conclusions: Although the rapid brain atrophy and short life-span of the R6/2 model constitute adverse conditions to detect potentially delayed treatment effects, significant technical hurdles, such as poor cell survival and differentiation, were also sub-optimal. Further consideration of these aspects is therefore needed in more enduring transgenic HD models to provide a definite assessment of this cell line's therapeutic relevance. However, a combination of treatments is likely needed to affect outcome in transgenic models of HD. © 2012 El Akabawy et al.; licensee BioMed Central Ltd.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3502570/bin/1471-2202-13-97-S1.tiff
https://efashare.b-cdn.net/share/pmc/articles/PMC3502570/bin/1471-2202-13-97-S2.jpeg
https://efashare.b-cdn.net/share/pmc/articles/PMC3502570/bin/1471-2202-13-97-S3.tiff
https://efashare.b-cdn.net/share/pmc/articles/PMC3502570/bin/1471-2202-13-97-S4.tiff
Authors & Co-Authors
El-Akabawy, Gehan Farouk Ali
United Kingdom, London
King's College London
Egypt, Shibin el Kom
Menoufia University Faculty of Medicine
Rattray, Ivan
United Kingdom, London
King's College London
Johansson, Saga M.
United Kingdom, London
King's College London
Gale, Richard
United Kingdom, London
Guy's Hospital
Bates, Gillian P.
United Kingdom, London
Guy's Hospital
Modo, Michel M.J.
United Kingdom, London
King's College London
United States, Pittsburgh
Mcgowan Institute for Regenerative Medicine
Statistics
Citations: 6
Authors: 6
Affiliations: 4
Identifiers
Doi:
10.1186/1471-2202-13-97
e-ISSN:
14712202
Research Areas
Cancer
Genetics And Genomics